Neurocrine Biosciences (NASDAQ:NBIX) Director Sells $44,700.00 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director George Morrow sold 300 shares of the business’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $149.00, for a total transaction of $44,700.00. Following the sale, the director owned 10,386 shares of the company’s stock, valued at approximately $1,547,514. This represents a 2.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $159.76 on Friday. The business’s fifty day moving average price is $147.04 and its 200-day moving average price is $147.90. The stock has a market capitalization of $16.17 billion, a price-to-earnings ratio of 23.70, a PEG ratio of 0.74 and a beta of 0.36. Neurocrine Biosciences, Inc. has a 1-year low of $122.14 and a 1-year high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Monday, November 2nd. The company reported $3.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.91 by $1.38. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.04 billion. Neurocrine Biosciences had a return on equity of 23.39% and a net margin of 18.98%. The company’s revenue for the quarter was up 41.3% on a year-over-year basis. During the same period last year, the business posted $2.04 EPS. Equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 7.66 EPS for the current year.

Key Headlines Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported third-quarter revenue of $1.12 billion, up 41% year over year and above estimates, with EPS of $3.29 versus a $1.91 consensus. The company also raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, reinforcing the growth case for its leading product. Q3 results and outlook
• Positive Sentiment: New survey findings showed fewer work or school disruptions among adults with tardive dyskinesia after starting INGREZZA: the share reporting disruptions fell from 57% to 21%, and average missed days declined from 5.6 to 2.0 per month. The results may bolster confidence in the treatment’s patient benefits. INGREZZA survey findings
• Positive Sentiment: Analysts raised price targets following the earnings report, including Morgan Stanley, Canaccord Genuity, RBC and Piper Sandler. Guggenheim also lifted its target to $224 and maintained a Buy rating, adding to the supportive analyst backdrop. Guggenheim rating
• Neutral Sentiment: After a sharp post-earnings advance, some investors may be taking profits, which could weigh on the shares despite the strong operating update. A director’s sale of 300 shares was made under a pre-arranged trading plan and appears small relative to his remaining holdings.
• Negative Sentiment: A report flagged potential integration challenges and legacy liabilities related to Neurocrine’s Soleno acquisition, risks that could complicate the expected value from the deal. Soleno acquisition risks

Hedge Funds Weigh In On Neurocrine Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE grew its stake in Neurocrine Biosciences by 10.6% in the 1st quarter. Bank of America Corp DE now owns 583,827 shares of the company’s stock worth $76,913,000 after acquiring an additional 55,723 shares in the last quarter. ABN AMRO Bank N.V. purchased a new position in shares of Neurocrine Biosciences during the second quarter worth approximately $2,510,000. Focus Partners Advisor Solutions LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter valued at approximately $1,927,000. Engineers Gate Manager LP raised its stake in shares of Neurocrine Biosciences by 64.0% during the second quarter. Engineers Gate Manager LP now owns 18,361 shares of the company’s stock valued at $3,094,000 after acquiring an additional 7,163 shares in the last quarter. Finally, SEB Asset Management AB bought a new stake in shares of Neurocrine Biosciences during the first quarter valued at approximately $10,483,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on NBIX shares. Citigroup boosted their price target on Neurocrine Biosciences from $249.00 to $253.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. Wall Street Zen cut shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Sunday, August 9th. Wedbush raised their price objective on shares of Neurocrine Biosciences from $185.00 to $194.00 and gave the stock an “outperform” rating in a report on Monday, August 3rd. Cantor Fitzgerald raised their price objective on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Finally, Needham & Company LLC restated a “buy” rating and set a $204.00 target price on shares of Neurocrine Biosciences in a research report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $202.32.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.